3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
52
Paclitaxel
19
Cisplatin
14
Carboplatin
14
lenvatinib
10
Docetaxel
8
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled